<ClinicalUseDefinition xmlns="http://hl7.org/fhir"><id value="example-indication"/><contained><Group><id value="group"/><type value="person"/><membership value="definitional"/><characteristic><code><coding><system value="http://ema.europa.eu/example/characteristic"/><code value="age-range"/></coding></code><valueRange><low><value value="18"/><unit value="a"/></low></valueRange><exclude value="false"/></characteristic></Group></contained><extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"><valueCode value="brr"/></extension><type value="indication"/><subject><reference><reference value="MedicinalProductDefinition/example"/></reference></subject><indication><diseaseSymptomProcedure><concept><coding><system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/><code value="Pulmonary-embolism-and-thrombosis-example-code"/></coding><text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."/></concept></diseaseSymptomProcedure><diseaseStatus><concept><coding><system value="http://ema.europa.eu/example/diseasestatus"/><code value="Recurrent"/></coding></concept></diseaseStatus><intendedEffect><concept><coding><system value="http://ema.europa.eu/example/intendedeffect"/><code value="PRYLX"/></coding></concept></intendedEffect></indication><population><reference value="#group"/></population></ClinicalUseDefinition>